Loading stock data…
LAB
$0.94+0.01 (+0.73%)
Market ClosedLast close May 1
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Standard BioTools Inc. in the Healthcare sector is trading at $0.94. The stock is currently near its 52-week low of $0.87, remaining 25.2% below its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why LAB maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.94
Potential Upside
5%
Whystock Fair Value$0.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$367.53M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.40%
Volume
Today's trading volume
2.22M
Recent News
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock received 2 Hold ratings from analysts, with a projected median 1-year price target of $1.35. This yields an impressive upside potential of […]
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Standard BioTools: Q4 Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had net income of 5 cents. Earnings, adjusted for one-time gains and costs, came to 6 cents per share. The company that makes equipment to control fluids posted revenue of $23.8 million in the period.
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...